Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20580580 | 0.82 | SSTR4 (0.38) | SSTR4SYKPAX8SOS1 | |
| SCHEMBL31330243 | 0.82 | SSTR4 (0.44) | SSTR4SYKMTNR1AMTNR1BPAX8 | |
| SCHEMBL29736597 | 0.82 | SSTR4 (0.44) | SSTR4SYKMTNR1AMTNR1BPAX8 | |
| SCHEMBL24103634 | 0.81 | SSTR4 (0.43) | SSTR4SYKPAX8SOS1 | |
| SCHEMBL30420159 | 0.81 | SSTR4 (0.43) | SSTR4SYKPAX8SOS1 | |
| SCHEMBL23089228 | 0.81 | SYK (0.37) | SSTR4SYKAAK1SOS1 | |
| SCHEMBL29424938 | 0.81 | SYK (0.37) | SSTR4SYKAAK1SOS1 | |
| SCHEMBL23107325 | 0.80 | SSTR4 (0.37) | SSTR4SYKPAX8SOS1 | |
| SCHEMBL24103619 | 0.80 | SSTR4 (0.37) | SSTR4SYKPAX8SOS1 | |
| SCHEMBL29845582 | 0.80 | SSTR4 (0.37) | SSTR4SYKPAX8SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289753-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-09-15 | — | — | US | disclosed |
| CN-114728935-A | SHP2 inhibitor | IRBM股份公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4010335-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021028362-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289753-A1 | SHP2 INHIBITORS | PTPN1, PTPN2, PTPN7 | SSTR4 3589/4885SYK 122/4885MTNR1A 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.